Finanzas de Compass Therapeutics Inc. (CMPX)CMPXCompass Therapeutics Inc.

Evaluating the bottom line, Compass Therapeutics Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -56.66%, provide a clear picture of how effectively CMPX converts its operational activities into shareholder value.

In the context of the broader market, CMPX competes directly with industry leaders such as IPHA and MENS. With a market capitalization of $123.29M, it holds a significant position in the sector. When comparing efficiency, CMPX's gross margin of N/A stands against IPHA's 66.04% and MENS's N/A. Such benchmarking helps identify whether Compass Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

The financial performance of Compass Therapeutics is concerning, with a consistent negative net income reported, including a loss of $25,154,000 in Q2 2026. The gross margin has been zero for several quarters, indicating no revenue generation, and the company has a forward P/E of 0, reflecting no earnings forecasted in the near term.